已收录 268921 条政策
 政策提纲
  • 暂无提纲
ABO Genotyping of Complete Hydatidiform Moles
[摘要] It has been suggested that the ABO blood group of a patient and her partner influence the clinical outcome for patients having a pregnancy with a complete hydatidiform mole (CHM). Since CHM lack red blood Cells, it has not previously been possible to type CHM serologically and investigate the relationship between the blood group of the CHM and that of the patient. In the present study we have demonstrated the feasibility of using molecular genotyping to determine the ABO genotype of CHM, the ABO genotype being consistent with the androgenetic origin of CHM in all cases. In the series of 48 cases of CHM, the requirement for chemotherapy was not significantly different in those patients with a CHM of like blood group compared with those with a CHM of unlike blood group.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 生理学与病理学
[关键词]  [时效性] 
   浏览次数:1      统一登录查看全文      激活码登录查看全文